Skip to main content
Premium Trial:

Request an Annual Quote

Peter Dansky, Kip Miller, Nicolas Barthelemy, Laura Lauman, David Hoffmeister, Bernd Brust, Peter Leddy, Mark O'Donnell, John Cottingham, Paul Grossman, Joe Beery, Brian Pollock, Mark Smedley, Victor Ambros

Premium
Invitrogen and Applied Biosystems have named the executives that will lead the four divisions of the merged company.
 
The molecular biology systems division will be led by Peter Dansky, who currently serves as leader of ABI’s molecular and cell biology functional analysis division.
 
The genetic systems division will be led by Kip Miller, who is currently leader of Invitrogen’s biodiscovery division. It will include ABI’s capillary electrophoresis and SOLiD sequencing systems, as well as Invitrogen’s third-generation sequencing development program.
 
The cell systems division will be led by Nicolas Barthelemy, who currently heads Invitrogen’s cell systems division.
 
The mass spectrometry division will be led by Laura Lauman, who currently leads ABI’s proteomics and small molecule division.
 
In addition, David Hoffmeister, currently Invitrogen’s CFO, will assume the same position at the new company; Bernd Brust, head of Invitrogen’s global sales and marketing, will lead global commercial operations; Peter Leddy, head of Invitrogen’s human resources, will become head of global human resources; Mark O’Donnell, now head of ABI's global services and supply chain, will lead global operations and services; John Cottingham, general counsel for Invitrogen, will become chief legal officer; Paul Grossman, Invitrogen’s lead for strategy and corporate development, will assume the same title; Joe Beery will keep his position as head of information technology at Invitrogen in the new company; Brian Pollock, CSO of Invitrogen, will be head of global research and development; and Mark Smedley will continue as full-time integration leader and head of the integration management office. He has been directing the integration efforts.
 

 
Victor Ambros is one of three recipients of the 2008 Lasker Award for Basic Medical Research. He is a professor of molecular medicine at the University of
Massachusetts Medical School. Ambros, who discovered microRNAs, is an early-access collaborator of Helicos BioSciences.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.